| Jul 31 2025 |
CODEX ALIMENTARIUS: Main Outcome of the 18th Committee Session on Contaminants in Food (CCCF18) |
Keller and Heckman LLP |
| Jul 31 2025 |
Kissing Cousins? SUNKIST and KIST Deemed Confusingly Similar |
McDermott Will & Emery |
| Jul 31 2025 |
Diagnosing Health Care: Can Food Really Be Medicine? Transforming Health Care One Bite at a Time [Podcast] |
Epstein Becker & Green, P.C. |
| Jul 31 2025 |
Can Food Really Be Medicine? Transforming Health Care One Bite at a Time |
Epstein Becker & Green, P.C. |
| Jul 31 2025 |
FDA’s Reagan-Udall Foundation Releases Roadmap to Produce Safety |
Keller and Heckman LLP |
| Jul 31 2025 |
FDA Announces FY 2026 User Fees |
Keller and Heckman LLP |
| Jul 31 2025 |
California’s Compostable Labeling Requirement Delayed, Varying Compostable Requirements in State’s Laws Questioned |
Keller and Heckman LLP |
| Jul 31 2025 |
FDA’s Chemistry Guidance Update Not Expected in 2025 |
Keller and Heckman LLP |
| Jul 31 2025 |
USDA APHIS Updates Petition Review Practices for Genetically Engineered Organisms |
Keller and Heckman LLP |
| Jul 30 2025 |
Global Regulatory Developments for June 2025 |
Bergeson & Campbell, P.C. |
| Jul 30 2025 |
CMS Proposes New Rules for Calculating Average Sales Price for Medicare Part B Drug Reimbursement |
Blank Rome LLP |
| Jul 30 2025 |
Texas and Louisiana Enact ‘MAHA’-Inspired Food Additive Legislation |
Greenberg Traurig, LLP |
| Jul 30 2025 |
This Week in 340B: July 22 – 28, 2025 |
McDermott Will & Emery |
| Jul 30 2025 |
Is Industrial Hemp on the Verge of Having Its Overdue Moment? |
Bradley Arant Boult Cummings LLP |
| Jul 30 2025 |
CMS Proposes New Standards for Bona Fide Service Fees in Average Sales Price Calculations: What Plans, PBMs, and Other Recipients of BFSFs Need to Know |
Mintz |
| Jul 29 2025 |
Federal Circuit Reverses Trademark Board: The KIST vs. SUNKIST Confusion |
Bradley Arant Boult Cummings LLP |
| Jul 28 2025 |
EC Scientific Committee Issues Final Opinion on Hydroxyapatite (Nano) in Oral Products |
Bergeson & Campbell, P.C. |
| Jul 28 2025 |
DOJ False Claims “Working Group” Update |
Sheppard, Mullin, Richter & Hampton LLP |
| Jul 28 2025 |
D.C. Download - S1, E3: Biotech Innovation [Podcast] |
Polsinelli PC |
| Jul 28 2025 |
Healthcare Preview for the Week of: July 28, 2025 [Podcast] |
McDermott Will & Emery |
| Jul 28 2025 |
DEA Judge Overseeing Rescheduling Process Retires, Further Casting Doubt on the Likelihood of Any Change in the Near Term |
Bradley Arant Boult Cummings LLP |
| Jul 28 2025 |
DOJ and FTC Host Second Session on Structural and Regulatory Impediments to Drug Competition |
Sheppard, Mullin, Richter & Hampton LLP |
| Jul 28 2025 |
California Construction Employers May Rely on Legal Exemption to Drug Test for Marijuana |
Jackson Lewis P.C. |
| Jul 28 2025 |
FinCEN Exercises New Authority Targeting Mexico-Based Financial Institutions to Counter Cartel-Linked Fentanyl Trade |
Foley & Lardner LLP |
| Jul 26 2025 |
EPA Seeks Nominations of Peer Reviewers to Evaluate Design Considerations for Genetically Engineered Mosquitoes |
Bergeson & Campbell, P.C. |
| Jul 25 2025 |
Texas and Louisiana Serve Up New Laws on Food Product Labels and Disclosures |
Katten |
| Jul 25 2025 |
McDermott+ Check-Up – July 25, 2025 |
McDermott Will & Emery |
| Jul 25 2025 |
Building an Exemption: California Construction Employers Allowed to Drug Test for Marijuana |
Jackson Lewis P.C. |
| Jul 24 2025 |
U.S. Senate Bill Would Eliminate Self-GRAS Pathway to Market Food Substances |
Keller and Heckman LLP |
| Jul 24 2025 |
Filling the Gaps and Navigating Fine Lines: Licensure Considerations for Medical Spas |
Mintz |
| Jul 24 2025 |
Louisiana and Texas Pass Laws Requiring Warning Labels for Certain Food Ingredients |
Beveridge & Diamond PC |
| Jul 24 2025 |
Who Can File an Ultra-Processed Food Lawsuit? |
Oberheiden P.C. |
| Jul 24 2025 |
USDA Announces Launch of a 5-Part Plan to Bolster Food Safety |
Keller and Heckman LLP |
| Jul 24 2025 |
FDA Approves New Natural Food Dye Derived from Gardenia Fruit |
Keller and Heckman LLP |
| Jul 24 2025 |
Impact of Recent CMS Rule on Site Neutrality and 340B Programs—Implications for Oncology Services |
Blank Rome LLP |
